AstraZeneca-Ionis Rare Disease Drug Data Shows Sustained Benefit; Under FDA Review
- Ionis Pharmaceuticals Inc released topline results from the 66-week analysis of Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca Plc's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) that leads to peripheral nerve damage and motor disability.
- At 66 weeks, patients treated with eplontersen demonstrated a statistically significant and clinically meaningful change from baseline versus an external placebo group on the co-primary endpoints of modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression and Quality of life.
- The study also met its third co-primary endpoint, demonstrating a statistically significant reduction in serum TTR concentration versus an external placebo group.
- TTR reductions were consistent with those reported at week 35.
- Eplontersen exhibited a safety and tolerability profile consistent with that observed at 35 weeks.
- Data from the 35 and 66-week analyses will be presented as an Emerging Science presentation at the April American Academy of Neurology Annual Meeting.
- Earlier this month, FDA accepted a marketing application for eplontersen with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S.
- Eplontersen is currently being evaluated in the Phase 3 CARDIO-TTRansform study for transthyretin amyloid cardiomyopathy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.